Get started

Financials · RCEL

Avita Medical Inc. (RCEL) financials

For the twelve months ended Sep 30, 2026, Avita Medical Inc. reported $84.68M of revenue and -$36.12M of net income.

Revenue, TTM
$84.68M
Revenue growth, YoY
+17.0%
Net income, TTM
-$36.12M
Net margin
-42.7%
Free cash flow, TTM
-$20.63M
EPS, diluted, TTM
-$1.17
Cash
$10.50M
Total debt
$45.48M
P/S
6.35
Market cap
$537.9M
Annual revenue$71.61M
FY2018FY2025
Annual net income-$48.59M
FY2018FY2025
Annual free cash flow-$32.20M
FY2018FY2025

RCEL revenue and earnings growth

RCEL revenueQ3 2026$26.11M

Quarter YoY
+53.1%
QoQ
+20.3%
FY YoY
+11.5%

RCEL revenue was $26.11M in fiscal Q3 2026 (ended Sep 30, 2026), up 53.1% from a year earlier and up 20.3% from the prior quarter. For the full fiscal 2025 it was $71.61M, up 11.5% from fiscal 2024. It rose in each of the last 3 fiscal years. Fiscal 2025 is the highest of the 8 fiscal years on file.

RCEL net incomeQ3 2026-$6.22M

RCEL net income was -$6.22M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$13.19M a year earlier. For the full fiscal 2025 it was -$48.59M, compared with -$61.84M in fiscal 2024.

RCEL EPSQ3 2026-$0.20

RCEL diluted EPS was -$0.20 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.46 a year earlier. For the full fiscal 2025 it was -$1.74, compared with -$2.39 in fiscal 2024.

RCEL free cash flowQ3 2026-$821.0K

RCEL free cash flow was -$821.0K in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$6.15M a year earlier. For the full fiscal 2025 it was -$32.20M, compared with -$58.11M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
FY2019
Jun 30, 2019
FY2018
Jun 30, 2018
Revenue$71.61M$64.25M$50.14M$34.42M$29.23M$14.26M$5.47M$929.0K
Cost of revenue$12.79M$9.09M$7.78M$6.04M$5.95M$2.97M$1.27M$546.0K
Gross profit$58.82M$55.16M$42.36M$28.38M$23.28M$11.29M$4.20M$383.0K
Research and development$20.84M$20.36M$20.82M$13.86M$14.82M$9.16M$8.00M$6.26M
Selling, general and admin$27.37M$33.20M$28.33M$23.33M$22.40M$33.02M$15.10M$9.40M
Operating income-$42.53M-$56.59M-$42.66M-$27.50M-$26.54M-$42.68M-$25.53M-$13.84M
Interest expense$5.00M$5.36M$1.14M$16.0K$22.0K$33.0K$27.0K$21.0K
Pre-tax income-$48.58M-$61.79M-$35.31M-$26.63M-$26.55M-$42.03M-$25.22M-$13.81M
Income tax$11.0K$54.0K$66.0K$36.0K$38.0K$4.0K-$121.0K-$1.07M
Net income-$48.59M-$61.84M-$35.38M-$26.66M-$26.58M-$42.03M-$25.10M-$12.73M
EPS, basic-$1.74-$2.39-$1.40$1.07$1.17$2.07$1.56$1.37
EPS, diluted-$1.74-$2.39-$1.40$1.07$1.17$2.07$1.56$1.37
Diluted shares27.9M25.9M25.3M25.0M22.7M20.3M16.1M9.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
FY2019
Jun 30, 2019
FY2018
Jun 30, 2018
Cash and equivalents$10.24M$14.05M$22.12M$18.16M$110.75M$73.84M$20.37M$10.99M
Short-term investments$7.94M$21.84M$66.94M$61.18M----
Receivables$9.09M$11.80M$7.66M$3.52M$3.47M$2.08M$1.40M-
Inventory$6.93M$7.27M$5.60M$2.13M$1.65M$1.13M$742.0K-
Current assets$35.49M$57.00M$104.01M$87.46M$121.33M$78.39M$24.13M-
Total assets$56.39M$79.71M$111.64M$98.26M$125.50M$82.46M$25.78M-
Current liabilities$62.68M$20.16M$13.20M$10.69M$7.39M$7.71M$4.48M-
Short-term debt$42.98M$0------
Long-term debt$0$42.24M$39.81M-----
Total debt$42.98M$42.24M$39.81M-----
Total liabilities$73.04M$74.97M$61.89M$12.97M$9.85M$10.06M$4.95M-
Shareholders' equity-$16.65M$4.50M$49.06M$84.74M$115.66M$72.40M$20.83M$14.03M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
FY2019
Jun 30, 2019
FY2018
Jun 30, 2018
Operating cash flow-$31.20M-$48.94M-$38.01M-$19.09M-$25.90M-$22.75M-$19.25M-$12.96M
Capital expenditures$1.00M$9.17M$1.38M$452.0K$894.0K$590.0K$1.02M$365.0K
Free cash flow-$32.20M-$58.11M-$39.39M-$19.54M-$26.80M-$23.34M-$20.27M-$13.32M
Investing cash flow$12.45M$37.36M$1.61M-$19.33M-$1.17M-$847.0K-$1.23M-$365.0K
Financing cash flow$14.94M$3.51M$40.37M$900.0K$64.05M$77.06M$29.71M$21.30M
Stock-based compensation$9.52M$13.50M$8.38M$7.00M$5.66M$16.49M$1.95M$1.42M
Depreciation and amortization$2.35M$1.13M$632.0K$568.0K$715.0K$465.0K$269.0K$110.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Jun 30, 2021
FY2020
Jun 30, 2020
FY2019
Jun 30, 2019
FY2018
Jun 30, 2018
Revenue growth, YoY11.5%28.1%45.7%17.8%104.9%160.6%489.2%-
EPS growth, YoY----8.5%-43.5%32.7%--
Gross margin82.1%85.8%84.5%82.4%79.6%79.2%76.8%41.2%
Operating margin-59.4%-88.1%-85.1%-79.9%-90.8%-299.2%-466.4%-1489.9%
Net margin-67.8%-96.3%-70.6%-77.5%-90.9%-294.7%-458.6%-1370.8%
Free cash flow margin-45.0%-90.4%-78.6%-56.8%-91.7%-163.6%-370.3%-1434.3%
Return on equity--1374.6%-72.1%-31.5%-23.0%-58.1%-120.5%-90.8%
Return on assets-86.2%-77.6%-31.7%-27.1%-21.2%-51.0%-97.4%-
Current ratio0.572.837.888.1816.4210.175.38-
Debt to equity-9.390.81-----

Source: XBRL data Avita Medical Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RCEL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RCEL$84.68M+17.0%-$36.12M-42.7%$537.9M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

RCEL FAQ

9 questions
  • What is RCEL revenue?
    Avita Medical Inc. (RCEL) reported $84.68M of revenue for the twelve months ended Sep 30, 2026. That is up 17.0% from the year before. Revenue for fiscal 2025 was $71.61M.
  • Is RCEL profitable?
    No. Avita Medical Inc. reported a net loss of $36.12M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does RCEL have?
    Avita Medical Inc. reported $10.50M in cash and cash equivalents and $45.48M of debt on its most recent balance sheet in SEC filings.
  • How fast is RCEL revenue growing?
    Avita Medical Inc.'s revenue changed +11.5% in fiscal 2025, to $71.61M.
  • What is RCEL gross margin?
    Avita Medical Inc.'s gross profit was $69.75M on $84.68M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 82.4%.
  • What is RCEL free cash flow?
    Avita Medical Inc. generated -$20.63M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$19.72M less capital expenditures.
  • What is RCEL earnings per share?
    Diluted earnings per share were -$1.17 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did RCEL last report financial results?
    The latest statements here come from Avita Medical Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this RCEL financial data come from?
    Quantisnow builds these statements from the structured XBRL data Avita Medical Inc. files with the SEC. It is provided for information only and is not investment advice.